WebJan 23, 2024 · Objective: To perform a systematic review of studies of lurasidone in children and/or adolescents and to present a case report aimed to add further insights into its use in clinical practice with youth. Methods: We searched the following databases for empirical studies, of any design, focusing on the pharmacokinetics, efficacy, or safety of … WebLurasidone is available in 20, 40, 60, 80, and 120 mg tablets. The recommended starting dose is 40 mg/day for adults and adolescents with schizophrenia, with a recommended …
Lurasidone in Children and Adolescents: Systematic …
WebIf lurasidone is the problem, you’ll stop taking it right away. Common Side Effects in the Young Teens (13-17) with schizophrenia who take this drug most often have: Sleepiness … WebDec 3, 2024 · Lurasidone is a second-generation antipsychotic agent that is approved for the treatment of bipolar depression in adults as monotherapy and as adjunctive therapy with lithium or valproate (Loebel et al. 2014a, b) and in children and adolescents as monotherapy (Delbello et al. 2024) in the United States and elsewhere. iias reports
National Center for Biotechnology Information
WebJan 28, 2024 · Sunovion Announces that U.S. FDA Approves Latuda® (lurasidone HCl) for the Treatment of Schizophrenia in Adolescents (13-17 Years) Contacts Sunovion Pharmaceuticals Inc. Kristina Coppola,... WebLurasidone, sold under the trade name Latuda among others, is an antipsychotic medication used to treat schizophrenia and bipolar disorder. It is taken by mouth. Common side effects include sleepiness, movement disorders, nausea, and diarrhea. Serious side effects are valid for all atypical antipsychotics and may include the potentially permanent … WebJun 21, 2024 · Lurasidone is a second-generation (atypical) antipsychotic. It was initially approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with schizophrenia. ... In January 2024, lurasidone received FDA approval for the treatment of schizophrenia in adolescents. In March 2024, the FDA expanded the usage to include ... iia south west